ZVRA Ключевая статистика
Максимум
9.99
Открыть
9.53
Объем
1.51M
Минимум
9.47
Предыдущее закрытие
9.53
Объем торгов
14.76M
Макс. 52 нед.
15.04
Отн. объем
0.961
Амплитуда (%)
5.46%
Мин. 52 нед.
7.16
Коэф. оборота
2.57%
Рыночная капитализация
563.07M
P/E (TTM)
4.42
P/E (год.)
6.807
P/B
2.74
P/S
4.61
Прибыль на акцию (EPS)
2.154
Дивиденд (TTM)
0
Дивидендная доходность
0.00%
Акции в обращении
59.11M
Валюта
USD
ZVRA Доходность цены
7 день
30 день
90 день
180 день
С начала года
1 Год
ZVRA Распределение денежных потоков
ZVRA Дневной объем коротких продаж
ZVRA История short interest
Обзор акции ZVRA
As of 2026-07-27, the Zevra Therapeutics, Inc. (ZVRA) stock price today is 9.71. Based on this price, the company has a market capitalization of $563.07M, with a P/E ratio of 4.42.
On 2026-07-27, ZVRA traded between 9.47 and 9.99. Today’s stock price is 2.53% above the daily low and 2.80% below the daily high, placing ZVRA примерно в середине its most recent trading range.
Trading volume currently stands at 1.51M, compared with an average daily volume of 1.58M. This suggests that trading activity is примерно соответствует обычному уровню than usual.
Over the past year, Zevra Therapeutics, Inc. shares have traded between 7.16 and 15.04. At today’s price, ZVRA is 35.61% above its 52-week low and 35.44% below its 52-week high.
ZVRA Связанные новости
О нас ZVRA
Название компании
Zevra Therapeutics, Inc.
Сектор
Health Technology
Отрасль
Pharmaceuticals: Major
Биржи
Nasdaq
Количество сотрудников
61
Размер лота
100
Официальный сайт
Валюта
USD
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Related Stocks
ZVRA FAQ
© 2026 CoinGlass, all rights reserved
